Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease

Tony D’Urzo*, James F. Donohue, David Price, Marc Miravitlles, Edward Kerwin

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)


Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β<inf>2</inf> adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.

Original languageEnglish
Pages (from-to)519-532
Number of pages14
JournalExpert Review of Respiratory Medicine
Issue number5
Early online date24 Aug 2015
Publication statusPublished - 2015


  • aclidinium bromide
  • bronchodilation
  • chronic obstructive pulmonary disease
  • combination therapy
  • dyspnea
  • formoterol fumarate
  • long-acting muscarinic antagonist
  • long-acting β2-agonist
  • symptoms

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this